<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A new anti-CD24 immunotoxin (IT), SWA11.dgA, was constructed by coupling the MAb SWA11 via the bivalent linker SMPT to deglycosylated ricin A-chain (dgA) </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of SWA11.dgA were evaluated in vitro against the B-precursor <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell line REH, the non-B-non-T <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> cell line NALM-6 and the Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-2 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-38 </plain></SENT>
<SENT sid="2" pm="."><plain>Binding of SWA11 to the CD24 antigen was assessed by flow cytometry demonstrating high affinity of the MAb for <z:hpo ids='HP_0000001'>all</z:hpo> cell lines tested </plain></SENT>
<SENT sid="3" pm="."><plain>SWA11.dgA inhibited the protein synthesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-38, NALM-6, REH and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-2 cells by 50% at concentrations (IC50) of 4.0 x 10(-11) M, 6.0 x 10(-11) M, 8.0 x 10(-11) M and 3.0 x 10(-9) M, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>SWA11.dgA was subsequently used for the treatment of disseminated human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-38 Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in a newly developed <z:mp ids='MP_0002536'>SCID</z:mp> mouse model </plain></SENT>
<SENT sid="5" pm="."><plain>The mean survival time (MST) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-38-bearing <z:mp ids='MP_0002536'>SCID</z:mp> mice was extended from 23 days in untreated controls to more than 230 days when 6 microg SWA11.dgA was applied intraperitoneally one day after <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> challenge </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the animals achieved continuous complete remissions </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0002536'>SCID</z:mp> mice treated with SWA11.dgA 4 days after <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell challenge or a reduced dose of SWA11.dgA (67%) also had a significantly extended MST (45.0 and 51.4 days, respectively, as compared to 22.7 and 23.1 days in the controls) </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that SWA11.dgA might be of potential use for the treatment of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in man </plain></SENT>
</text></document>